PL2459715T3 - Sposób oczyszczania rekombinowanego adamts13 i innych białek oraz ich kompozycje - Google Patents

Sposób oczyszczania rekombinowanego adamts13 i innych białek oraz ich kompozycje

Info

Publication number
PL2459715T3
PL2459715T3 PL10737917T PL10737917T PL2459715T3 PL 2459715 T3 PL2459715 T3 PL 2459715T3 PL 10737917 T PL10737917 T PL 10737917T PL 10737917 T PL10737917 T PL 10737917T PL 2459715 T3 PL2459715 T3 PL 2459715T3
Authority
PL
Poland
Prior art keywords
proteins
compositions
purifying recombinant
recombinant adamts13
adamts13
Prior art date
Application number
PL10737917T
Other languages
English (en)
Inventor
Meinhard Hasslacher
Artur Mitterer
Christian Fiedler
Christa Mayer
Original Assignee
Baxalta GmbH
Baxalta Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH, Baxalta Incorporated filed Critical Baxalta GmbH
Publication of PL2459715T3 publication Critical patent/PL2459715T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/12—Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/14—Enzymes or microbial cells immobilised on or in an inorganic carrier
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Sustainable Development (AREA)
  • Inorganic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Water Supply & Treatment (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL10737917T 2009-07-31 2010-08-02 Sposób oczyszczania rekombinowanego adamts13 i innych białek oraz ich kompozycje PL2459715T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23030809P 2009-07-31 2009-07-31
PCT/EP2010/061192 WO2011012726A2 (en) 2009-07-31 2010-08-02 Method for purifying recombinant adamts13 and other proteins and compositions thereof
EP10737917.4A EP2459715B1 (en) 2009-07-31 2010-08-02 Method for purifying recombinant adamts13 and other proteins and compositions thereof

Publications (1)

Publication Number Publication Date
PL2459715T3 true PL2459715T3 (pl) 2020-04-30

Family

ID=42588355

Family Applications (2)

Application Number Title Priority Date Filing Date
PL17155619.4T PL3211077T3 (pl) 2009-07-31 2010-08-02 Sposoby oczyszczania rekombinowanego adamts13 i innych białek oraz ich kompozycje
PL10737917T PL2459715T3 (pl) 2009-07-31 2010-08-02 Sposób oczyszczania rekombinowanego adamts13 i innych białek oraz ich kompozycje

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL17155619.4T PL3211077T3 (pl) 2009-07-31 2010-08-02 Sposoby oczyszczania rekombinowanego adamts13 i innych białek oraz ich kompozycje

Country Status (22)

Country Link
US (4) US8945895B2 (pl)
EP (3) EP3211077B1 (pl)
JP (6) JP5907869B2 (pl)
KR (7) KR20190122272A (pl)
CN (3) CN107988192A (pl)
AU (1) AU2010277491B2 (pl)
CA (2) CA2916508A1 (pl)
CO (1) CO6612194A2 (pl)
DK (1) DK2459715T3 (pl)
EA (3) EA023783B1 (pl)
ES (3) ES3000382T3 (pl)
HR (1) HRP20192303T1 (pl)
HU (1) HUE046909T2 (pl)
IN (1) IN2012DN00907A (pl)
LT (1) LT2459715T (pl)
MX (2) MX2012001263A (pl)
NZ (2) NZ597756A (pl)
PL (2) PL3211077T3 (pl)
PT (1) PT2459715T (pl)
SG (2) SG193855A1 (pl)
SI (1) SI2459715T1 (pl)
WO (1) WO2011012726A2 (pl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2134360T3 (en) 2007-03-14 2016-02-22 Takeda Vaccines Inc Purification of virus-like particle
FR2918375B1 (fr) * 2007-07-05 2009-10-16 Lab Francais Du Fractionnement Utilisation d'un support de chromatographie pour reduire la quantite d'adamts13 dans une solution derivee du plasma
US8945895B2 (en) * 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
EP3456837A3 (en) * 2011-03-14 2019-04-24 Catalent Pharma Solutions, LLC Decorin compositions and use thereof
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9096648B2 (en) 2011-08-19 2015-08-04 Emd Millipore Corporation Methods of reducing level of one or more impurities in a sample during protein purification
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
DK3103861T3 (da) * 2012-06-21 2020-11-16 Baxalta GmbH Virusfiltrering af cellekulturmedier
JOP20130186B1 (ar) * 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
AU2014205441B2 (en) * 2013-01-09 2019-12-12 Takeda Pharmaceutical Company Limited Methods for purification of arylsulfatase A
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) * 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US8859252B1 (en) 2014-01-02 2014-10-14 Aerial Biopharma, Llc Prostatic acid phosphatase, compositions comprising the same, and methods for producing and/or purifying the same
KR102382402B1 (ko) 2014-02-04 2022-04-01 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
US11191818B2 (en) 2016-08-04 2021-12-07 Takeda Pharmaceutical Company Limited Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome
MX2020004151A (es) 2017-10-30 2020-08-13 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos.
JP2021519339A (ja) * 2018-04-03 2021-08-10 メルク パテント ゲーエムベーハー Ｃｅｘクロマトグラフィー媒体及び生物製剤供給原料からの標的タンパク質の低塩溶出
KR102140531B1 (ko) * 2018-08-07 2020-08-04 (주)휴온스 Gly-Tβ4의 제조방법
KR20210149117A (ko) * 2019-04-03 2021-12-08 젠자임 코포레이션 재조합 단백질의 연속 생산
WO2021067668A1 (en) 2019-10-04 2021-04-08 The Children's Medical Center Corporation Adamts13 treatment to enhance graft survival
US11821000B2 (en) * 2020-11-10 2023-11-21 Dionex Corporation Method of separating viral vectors
EP4408876A1 (en) * 2021-09-30 2024-08-07 Ichnos Sciences SA Methods of inactivating viral contaminants with a mixture of solvent and detergent
EP4490179A1 (en) 2022-03-07 2025-01-15 Takeda Pharmaceutical Company Limited Affinity chromatographic production of clinical human igg products
TW202400238A (zh) * 2022-05-10 2024-01-01 南韓商綠十字股份有限公司 血漿蛋白之新穎液體調配物
KR20230159285A (ko) * 2022-05-10 2023-11-21 주식회사 녹십자 혈장 단백질의 동결 건조를 위한 신규한 액상 제형물
WO2025181559A1 (en) * 2024-02-29 2025-09-04 Sloiron, Inc. Methods for determining the amount of encapsulated and free iron in a sample
US20250334572A1 (en) * 2024-04-26 2025-10-30 Waters Technologies Corporation Host cell protein detection using lateral flow devices

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239854A (en) * 1978-04-24 1980-12-16 Sumitomo Chemical Company, Limited Enzyme-immobilization carriers and preparation thereof
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US5283182A (en) * 1986-09-17 1994-02-01 Beecham Group Plc Preparation of immobilized hydantoinase stabilized with divalent metal ions
CA1339946C (en) * 1987-03-31 1998-07-07 Michael J. Griffith Ultrapurification process for polypeptides
US5792835A (en) * 1991-09-05 1998-08-11 Baxter International Inc. Method of preparing a topical fibrinogen complex
FR2681867B1 (fr) 1991-09-26 1993-12-31 Pasteur Merieux Serums Vaccins Procede de purification du facteur viii et preparations obtenues.
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
JP4260877B2 (ja) 1992-03-02 2009-04-30 バイオエング・インコーポレーテッド ウイルスの不活性化方法
US5296228A (en) * 1992-03-13 1994-03-22 Allergan, Inc. Compositions for controlled delivery of pharmaceutical compounds
US5288853A (en) 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
US5578480A (en) * 1993-04-23 1996-11-26 American Cyanamid Company Methods for the isolation and purification of the recombinantly expressed chondroitinase I and II enzymes from P. vulgaris
GB9503750D0 (en) * 1995-02-24 1995-04-12 Common Services Agency Thrombin preparation
US5688912A (en) 1995-09-22 1997-11-18 Bayer Corporation Peptide ligands which bind to von willebrand factor
US5831003A (en) 1996-06-28 1998-11-03 Bayer Corporation Peptides which bind to prothrombin and thrombin
US5786458A (en) * 1996-06-28 1998-07-28 Bayer Corporation Selective stabilization of protein during viral inactivation
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
US6429192B1 (en) 1998-06-10 2002-08-06 Statens Serum Institut Purification process for production of mannan-binding lectin and an MBL medicinal product
US6251860B1 (en) * 1998-07-07 2001-06-26 Suomen Punainen Risti Veripalvelu Pharmaceutical preparations
US6214221B1 (en) * 1999-02-22 2001-04-10 Henry B. Kopf Method and apparatus for purification of biological substances
US6451978B2 (en) * 2000-01-21 2002-09-17 Biovitrum Ab Purification of antithrombin-III-α and β
IL136552A (en) * 2000-06-05 2005-05-17 Omrix Biopharmaceuticals Ltd Method for the inactivation of viruses by a solvent - detergent combination and by nanofiltration
AU2001294218A1 (en) * 2000-10-11 2002-04-22 Kazusa Dna Research Institute Foundation Novel adamts family polypeptide and gene encoding the same
US6926894B2 (en) 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
CN1230526C (zh) * 2001-02-27 2005-12-07 成都夸常科技有限公司 一种除去作为病毒灭活剂的有机溶剂和/或去污剂的方法
US7037658B2 (en) 2001-08-16 2006-05-02 Regents Of University Of Michigan Methods and compositions for detecting variant ADAMTS13 genes
JP2003144154A (ja) * 2001-11-14 2003-05-20 Mitsubishi Pharma Corp 新規なａｄａｍｔｓファミリーポリペプチドおよびそれをコードする遺伝子
AU2002347152A1 (en) * 2001-12-05 2003-06-17 Cangene Corporation Immune globulin formulations for the treatment and prevention of an orthopoxvirus infection
US20030133829A1 (en) * 2001-12-21 2003-07-17 Baxter Healthcare Corporation Process for inactivating pathogens in a biological material
WO2003059935A2 (en) 2001-12-21 2003-07-24 Immunex Corporation Methods for purifying protein
GB0216002D0 (en) * 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
GB0216001D0 (en) 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
WO2004035778A1 (ja) * 2002-10-18 2004-04-29 Japan As Represented By The President Of National Cardiovascular Center フォンビルブランド因子切断酵素の特異的基質および活性測定法
ATE480557T1 (de) 2003-07-09 2010-09-15 Shionogi & Co Inducer von atopischer dermatitis
CA2487673C (en) * 2003-12-02 2010-11-02 F. Hoffmann-La Roche Ag Improved method for the recombinant production and purification of protein kinases
GB0405330D0 (en) * 2004-03-10 2004-04-21 Astrazeneca Ab Enzyme and preparation method
US20080138790A1 (en) * 2004-04-13 2008-06-12 Winslow Robert M Methods and Compositions for Simultaneously Isolating Hemoglobin from Red Blood Cells and Inactivating Viruses
EP3127916A1 (en) 2004-06-07 2017-02-08 Therapure Biopharma Inc. Isolation of plasma or serum proteins
US7270976B2 (en) * 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
US7515392B2 (en) 2004-07-28 2009-04-07 Texas Instruments Incorporated High voltage circuits implemented using low voltage transistors
DE102004044419B4 (de) * 2004-09-14 2010-04-15 Biotest Ag Verfahren zur Aufreinigung eines von Willebrand Faktors mittels Hydroxylapatit-Durchlaufchromatographie
JP2006083044A (ja) 2004-09-17 2006-03-30 Hitachi Ltd ガラス部材
EP1838333A1 (en) * 2005-01-05 2007-10-03 Foundation For Fatal Rare Disease Pharmaceutically active antiviral peptides
US20060193966A1 (en) * 2005-02-28 2006-08-31 Shaowen Wu Multi-anion treated soy proteins and methods for preparation thereof
WO2006133955A1 (en) 2005-06-17 2006-12-21 Baxter International Inc. Adamts13-comprising compositions having thrombolytic activity
FR2887883B1 (fr) 2005-06-29 2007-08-31 Lab Francais Du Fractionnement Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines
US7506514B2 (en) 2005-06-30 2009-03-24 United Technologies Corporation Augmentor fuel conduit bushing
CN101379077A (zh) * 2005-12-07 2009-03-04 夏洛特·豪泽 因子ⅷ和因子ⅷ-类似蛋白的小肽或者拟肽亲合性配体
JP5067917B2 (ja) 2005-12-28 2012-11-07 アルフレッサファーマ株式会社 Ａｄａｍｔｓ１３の分離精製方法
ES2386574T3 (es) 2006-02-16 2012-08-23 Mitsubishi Chemical Medience Corporation Procedimiento de detección de afección en paciente con alteración de la consciencia
US7468258B2 (en) 2006-03-07 2008-12-23 Wake Forest University Health Sciences Self-quenching homofluorophore compositions for detecting enzyme activity
WO2008057074A1 (en) * 2006-11-06 2008-05-15 Millipore Corporation Method of flow-through chromatography
JP5505853B2 (ja) 2007-02-13 2014-05-28 味の素株式会社 微酸性アルギニンを添加剤とするウイルス不活化法
EP2374878B1 (en) 2007-06-22 2015-08-19 The Chemo-Sero-Therapeutic Research Institute Novel adamts-13 mutant
FR2918375B1 (fr) * 2007-07-05 2009-10-16 Lab Francais Du Fractionnement Utilisation d'un support de chromatographie pour reduire la quantite d'adamts13 dans une solution derivee du plasma
US8399620B2 (en) 2007-07-11 2013-03-19 Novo Nordisk A/S Purification of factor VIII using a mixed-mode or multimodal resin
CA2698103A1 (en) * 2007-08-31 2009-03-05 Amgen Inc. Solid-state protein formulation
US20090130714A1 (en) * 2007-09-24 2009-05-21 Reliance Life Sciences Pvt.Ltd. Process for purifying recombinanat tissue plasminogen activator (TPA)
US8945895B2 (en) * 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof

Also Published As

Publication number Publication date
CN107988192A (zh) 2018-05-04
HRP20192303T1 (hr) 2020-10-02
CN102482660A (zh) 2012-05-30
EA034292B1 (ru) 2020-01-24
MX2012001263A (es) 2012-05-22
ES3039686T3 (en) 2025-10-23
KR20120053013A (ko) 2012-05-24
KR20190122272A (ko) 2019-10-29
WO2011012726A2 (en) 2011-02-03
US20260062691A1 (en) 2026-03-05
EP2459715B1 (en) 2019-10-02
JP2013500711A (ja) 2013-01-10
JP2015147815A (ja) 2015-08-20
ES2763207T3 (es) 2020-05-27
CA2916508A1 (en) 2011-02-03
CA2769362A1 (en) 2011-02-03
LT2459715T (lt) 2020-01-10
EP4299735B1 (en) 2025-05-21
EA201992487A1 (ru) 2020-05-31
KR20200146042A (ko) 2020-12-31
US20110081700A1 (en) 2011-04-07
EA023783B1 (ru) 2016-07-29
JP2018203781A (ja) 2018-12-27
JP5907869B2 (ja) 2016-04-26
SG178175A1 (en) 2012-03-29
KR20170096061A (ko) 2017-08-23
CN107267490A (zh) 2017-10-20
WO2011012726A3 (en) 2011-03-31
HUE046909T2 (hu) 2020-04-28
DK2459715T3 (da) 2020-01-06
ES3000382T3 (en) 2025-02-28
JP2016222724A (ja) 2016-12-28
US20150104849A1 (en) 2015-04-16
EA201270214A1 (ru) 2012-08-30
KR101883610B1 (ko) 2018-07-30
PL3211077T3 (pl) 2025-04-14
MX348178B (es) 2017-05-29
JP2022171925A (ja) 2022-11-11
NZ620988A (en) 2015-07-31
US11661593B2 (en) 2023-05-30
BR112012002140A2 (pt) 2015-09-15
AU2010277491A1 (en) 2012-02-16
KR101769634B1 (ko) 2017-08-18
SG193855A1 (en) 2013-10-30
PT2459715T (pt) 2020-01-09
SI2459715T1 (sl) 2020-01-31
JP2021004265A (ja) 2021-01-14
CO6612194A2 (es) 2013-02-01
EP3211077B1 (en) 2024-09-25
AU2010277491A2 (en) 2012-06-21
US20230242897A1 (en) 2023-08-03
IN2012DN00907A (pl) 2015-04-03
NZ597756A (en) 2014-03-28
EP4299735A2 (en) 2024-01-03
KR20230170815A (ko) 2023-12-19
EA201500952A1 (ru) 2016-05-31
US8945895B2 (en) 2015-02-03
EP3211077A1 (en) 2017-08-30
US12492390B2 (en) 2025-12-09
JP6216930B2 (ja) 2017-10-25
AU2010277491B2 (en) 2015-12-17
KR20220066435A (ko) 2022-05-24
EP4299735A3 (en) 2024-04-24
EP2459715A2 (en) 2012-06-06
KR20180087463A (ko) 2018-08-01

Similar Documents

Publication Publication Date Title
PL2459715T3 (pl) Sposób oczyszczania rekombinowanego adamts13 i innych białek oraz ich kompozycje
IL254498A0 (en) Methods for preparing purified polypeptide preparations
SI2522724T1 (sl) Postopek za spremembo polipeptida za čiščenje polipetidnih multimerov
SI3178490T1 (sl) Sestavki proteina F RSV-ja in postopki za pripravo le-teh
IL248880A0 (en) Preparations containing r-g-cysteic acid peptides and their uses
EP2379673A4 (en) SYSTEM AND METHOD FOR FRACTIONIZING BIOMASS
PL3715356T3 (pl) Sposób oczyszczania polipeptydów
GB0815872D0 (en) Novel method and compositions
EP2613857A4 (en) PROCESS FOR PURIFYING IMMUNOCONJUGATES OR ACTIVE POLYPEPTIDES
GB0922209D0 (en) Proteins, nucleic acid molecules and compositions
IL215234A0 (en) Method for purifying recombinant fsh
GB201012599D0 (en) Process for purifying proteins
IL219470A0 (en) Compositions containing fractalknie-binding proteins and uses thereof
ZA201102195B (en) Methods and compositions for isolating nucleic acid
GB0921076D0 (en) Handover system and method thereof
GB0912468D0 (en) Composition and method
PL2414092T3 (pl) Sposób i układ do mieszania zaczynu
SG10201507362TA (en) Novel Regulatory Proteins And Inhibitors
EP2395972A4 (en) PARTICULATE COMPOSITION AND METHOD FOR PRODUCING THE SAME
IL218261A0 (en) Method for purifying active gla-domain coagulation proteins
ZA201201436B (en) Method and system for polypeptide purification
IL218260A0 (en) Method for purifying gla-domain coagulation proteins
GB0901667D0 (en) Composition and method
EP2405001A4 (en) NUCLEIC ACID COMPLEX AND NUCLEIC ACID DELIVERING COMPOSITION
GB0908956D0 (en) Method and composition